USPTO 2015–2025 USPTO PatentsView US Corporation

Anika Therapeutics, Inc.

USPTO PatentsView assignee record - 7 granted patents across 11 technology areas, active 2019–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61B (DIAGNOSIS; SURGERY; IDENTIFICATION).

Compiled byPlainPatent Editorial, US Patent Intelligence Editorial Team · May 15, 2026

Explore the portfolio See the ranking

Total patents granted

CPC technology areas

15.1

Avg claims per patent

+500%

5-year filing velocity

The verdict

Anika holds 7 US patents across 11 technology areas, rank #34,149 of 50,000 tracked assignees.

#34,149
of 50,000 US assignees by volume: Top 17%
by Innovation Score (48.0/100): 15.1
avg claims per patent: +500%
filing velocity, last 5 yrs

Portfolio overview

Anika Therapeutics, Inc. has been granted 7 US utility patents between 2019 and 2025, placing Anika Therapeutics, Inc. at rank #34,149 across all assignees tracked by PlainPatent. This portfolio spans 11 distinct Cooperative Patent Classification (CPC) subclasses, averaging 15.1 claims per patent with primary concentration in A61B (DIAGNOSIS; SURGERY; IDENTIFICATION). As a US Corporation, Anika Therapeutics, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Anika sits between Anglo American Services (uk) Ltd (7 patents, rank #34,145) and Anritsu Infivis Co., Ltd. (7 patents, rank #34,153) - the closest US assignees by grant volume. The composite Innovation Score of 48.0/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 6 grants, compared with 1 in the 2015–2019 window, a +500% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Anika Therapeutics, Inc.'s 15.1 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 11 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Anika Therapeutics, Inc. against peers pursuing similar technology classes.

Anglo American Se…

7
ANHO Houseware Ji…

7
Anhui University…

7
ANI Pharmaceutica…

7
ANKO FOOD Machine

7
Annai Systems

7
Annexin Pharmaceu…

7
Anritsu Infivis

7
Anika Therapeutics ◀

7

What this shows Anika holds 7 patents at rank #34,149, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Anika

By rank, the assignees closest to #34,149 in granted patent volume.

Leaders in A61B (Diagnosis)

Other assignees with the most granted patents in Anika's primary technology class.

Anika's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

48 Top 17% higher than 83% of 50,000 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2019–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2019–2019 baseline. Full figures in the table below.

View data table

Anika Therapeutics, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2019	1	14.3%
2023	1	14.3%
2024	2	28.6%
2025	3	42.9%

Which technologies does Anika Therapeutics, Inc. patent most?

A61B - DIAGNOSIS; SURGERY; IDENTIFICATION 3

A61L - METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES 3

A61F - FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRS 2

A61P - SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS 2

A61K - PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES 2

F04C - ROTARY-PISTON, OR OSCILLATING-PISTON, POSITIVE-DISPLACEMENT MACHINES FOR LIQUIDS ; ROTARY-PISTON, OR OSCILLATING-PISTON, POSITIVE-DISPLACEMENT PUMPS 1

C08L - COMPOSITIONS OF MACROMOLECULAR COMPOUNDS 1

A61M - DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY ; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY ; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR 1

D03D - WOVEN FABRICS; METHODS OF WEAVING; LOOMS 1

D02G - CRIMPING OR CURLING FIBRES, FILAMENTS, THREADS, OR YARNS; YARNS OR THREADS 1

D10B - INDEXING SCHEME ASSOCIATED WITH SUBLASSES OF SECTION D, RELATING TO TEXTILES 1

Top 11 of 11 technology areas

Patent Moat Analysis

Portfolio Volume Light

Tech Breadth Focused

Claim Depth Standard

Velocity Accelerating

Where it ranks

Overall rank by patents

#34,149

Across all tracked assignees

Innovation Score

48.0 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does Anika Therapeutics, Inc. hold?

Anika Therapeutics, Inc. holds 7 US granted patents filed between 2019 and 2025, spanning 11 technology areas.

What is Anika Therapeutics, Inc.'s Innovation Score?

Anika Therapeutics, Inc. has an Innovation Score of 48.0 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Anika Therapeutics, Inc. focus on?

Anika Therapeutics, Inc.'s top technology area is A61B (DIAGNOSIS; SURGERY; IDENTIFICATION) with 3 patents. The company has filed patents in 11 CPC subclasses total.

Is Anika Therapeutics, Inc.'s patent filing rate increasing or decreasing?

Anika Therapeutics, Inc.'s recent filing velocity is +500% compared to the prior five-year period. This indicates accelerating innovation.

What does claim depth mean for Anika Therapeutics, Inc.'s patents?

Anika Therapeutics, Inc.'s patents average 15.1 claims each. This falls within the standard range, providing solid legal coverage.

How is the Anika Therapeutics, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

How to use this portfolio

Anika's 7 grants land it in the top 17% by Innovation Score, but volume alone doesn't tell you where the strength sits.

Read that count against the largest US assignees before treating it as dominance - Anika ranks #34,149 of 50,000. Top 50 holders
Most of this portfolio concentrates in A61B - see who else leads that technology area. A61B leaders
Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled byPlainPatent Editorial, US Patent Intelligence Editorial Team · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.